1. Barber, JA, Thompson, SG. Analysis of cost data in randomized trials: An application of the non-parametric bootstrap. Stat Med. 2000;19:3219–3236.
2. Berghella, V, Odibo, AO, To, MS, et al. Cerclage for short cervix on ultrasonography: Meta-analysis of trials using individual patient-level data. Obstet Gynecol. 2005;106:181–189.
3. Black, WC. The cost-effectiveness plane: A graphical representation of cost-effectiveness. Med Decis Making. 1990;10:212–214.
4. Blondel, B, Kogan, MD, Alexander, GR, et al. The impact of the increasing number of multiple births on the rates of preterm birth and low birthweight: An international study. Am J Pubic Health. 2002;92:1323–1330.
5. Caritis, SN, Rouse, DJ, Peaceman, AM, et al. Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: A randomized controlled trial. Obstet Gynecol. 2009;113 (pt 1):285–292.
6. Curtis, LA, ed. Unit costs of health and social care 2007. Canterbury, United Kingdom: Personal Social Services Research Unit, University of Kent; 2007.
7. Department of Health. National schedule for reference costs. London: DoH; 2008.
8. Dodd, JM, Flenady, VJ, Cincotta, R, Crowther, CA. Progesterone for the prevention of preterm birth: A systematic review. Obstet Gynecol. 2007;112:127–134.
9. Drummond, MF, O'Brien, B, Stoddart, GL, Torrance, G. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 1997.
10. Fenwick, E, Claxton, K, Sculpher, M. Representing uncertainty: The role of cost-effectiveness acceptability curves. Health Econ. 2001;10:779–787.
11. Hintz, SR, Kendrick, DE, Vohr, BR, et al. National Institute of Child Health and Human Development Neonatal Research Network. Changes in neurodevelopmental outcomes at 18 to 22 months’ corrected age among infants of less than 25 weeks’ gestational age born in 1993–1999. Pediatrics. 2005;115:1645–1651.
12. Lim, AC, Bloemenkamp, KWM, Boer, K, et al. Study protocol: Progesterone for the prevention of preterm birth in women with multiple pregnancies: The AMPHIA trial. BMC Pregnancy Childbirth. 2007;7:7.
13. Mugford, M, Hutton, G, Fox-Rushby, J. Methods for economic evaluation alongside a multicentre trial in developing countries: A case study form the WHO Antenatal Care Randomised Controlled Trial. Paediatr Perinat Epidemiol. 1998;12:75–97.
14. National Institute for Clinical Excellence (NICE). Guide to the methods of technology appraisal. NICE: London; 2004.
15. Norman, JN, Mackenzie, F, Owen, P, et al. A randomised, double blind placebo controlled STudy of Progesterone for the Prevention of Preterm Birth In Twins (STOPPIT), and a meta-analysis of the use of progesterone for prevention of preterm birth in twin pregnancy. Lancet. 2009;373:2034–2040.
17. Papiernik, E, Keith, L, Oleszczuk, JJ, Cervantes, A. What interventions are useful in reducing the rate of preterm delivery in twins? Clin Obstet Gynecol. 1998;41:13–23.
18. Petrou, S, Mehta, Z, Hockley, C, et al. The impact of preterm birth on hospital inpatient admissions and costs during the first five years of life. Pediatrics. 2003;112:1290–1297.
19. Petrou, S. Economic consequences of preterm birth and low birthweight. BJOG. 2003;110 (Suppl 20):17–23.
20. Raikou, M, Briggs, A, Gray, A, McGuire, A. Centre-specific or average unit costs in multi-centre studies? Some theory and simulation. Health Econ. 2000;9:191–198.
21. Repka, MX. Ophthalmological problems of the premature infant. Ment Retard Dev Disabil Res Rev. 2000;8:249–257.
22. Rouse, DJ, Caritis, SN, Peaceman, AM, et al. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Eng J Med. 2007;357:454–461
23. Stinnett, AA, Mullahy, J. Net health benefits: A new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making. 1998;18:S68–S80.
24. van Baar, AL, van Wassenaer, AG, Briet, JM, et al. Very preterm birth is associated with disabilities in multiple developmental domains. J Pediatr Psychol. 2005;30:247–255